About Us

Orbit Biomedical’s mission is to revolutionize gene and cell therapy treatment by setting a new standard for precise, targeted surgical delivery. Our focus is to transform the accuracy, safety and consistency of delivering curative therapeutics to patients.

Located near Philadelphia, Orbit Biomedical was founded in 2018 with a Series A investment from Syncona, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.


Focusing on precise, accurate targeted delivery

Building upon years of biomedical engineering and clinical development work, our current focus is on optimizing delivery to the subretinal space for the treatment of blinding eye diseases. Our novel investigational surgical system and training platform has been developed specifically for the purpose of delivering gene and cell therapies to the subretinal space.

Targeting minimal procedure-associated adverse events

By focusing on accuracy, safety and consistency of delivery, our goal is to help make the administration of one-time therapies, such as gene and cell therapies, as safe and effective as possible for patients. We work closely with biotech and pharmaceutical partners who are developing therapies to preserve or restore vision in patients suffering from sight-threatening ophthalmic diseases.

Designed to be standardized and consistent

In designing our technology, procedure and training program, we see consistency critical to minimize variability in delivery between patients and surgeons. We believe this will help to make curative therapies as scalable as possible.

Our Team

Susan Hill

Chief Executive Officer

Michael Keane

Chief Technology Officer

David E. Bourdeau

Chief Experience & Education Officer

Joel Sussman

Chief Financial Officer

Tim Carroll

Start-up CEO & Chief Business Officer

Karen Lott

Senior Manager, Clinical
Training Operations

Eileen O’Neill-Edgington

Office Manager